Descriptive analysis of incidence, demographic characteristics, and survival outcomes of soft-tissue sarcoma of the extremities in Saudi Arabia.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Soft-tissue sarcomas are uncommon, aggressive, and histologically heterogeneous, malignant tumors. Soft-tissue tumor types have different age and anatomical site distributions. This study aimed to assess the prevalence and incidence of soft-tissue sarcomas of the extremities to facilitate early diagnosis and intervention in the Kingdom of Saudi Arabia. This retrospective study included all patients diagnosed with primary soft-tissue sarcomas of the extremities and pelvis between January 2006 and December 2015. The data were obtained from the Saudi Cancer Registry. Means and confidence intervals were reported for numerical variables, whereas the frequencies and percentages were reported for categorical variables. The chi-squared test and analysis of variance were used to test the associations between categorical numerical variables. Cox regression analysis was used to determine the hazard ratios for each sarcoma type. Of the 659 patients, 145 (22%) were aged 19-30 years, 365 (55.4%) were men, and 411 (62.4%) had lower limb sarcoma. Most of the tumors (54.3%) were localized. The incidence of sarcoma ranged from 2 to 2.9 cases per one million (average, 2.4 cases per one million). Moreover, liposarcoma was the most commonly diagnosed (n = 135; 20.5%), followed by undifferentiated pleomorphic sarcoma (n = 87; 13.2%). The incidence of soft-tissue sarcomas in the Kingdom of Saudi Arabia were lower than those in Western countries. However, the distribution of soft-tissue sarcoma subtypes was similar to those in other countries. The survival rates in this study highlight the need for continued research and targeted interventions to improve the outcomes of patients with soft-tissue sarcomas, especially those with more aggressive subtypes, such as sarcoma not otherwise specified and rhabdomyosarcoma.